The study, presented at the annual meeting of the American Society of Hematology Dec. 9, designed a monobody with a simple protein framework and paired it with a drug called MMAE, which prevents cells from multiplying. The combination stopped abnormal growth in both cell tests and live animals, according to a Dec. 9 system news release.
“Our conjugate improved survival in early tests and has the potential to be important clinically against multiple myeloma,” senior author Dafna Bar-Sagi, PhD, senior vice president, vice dean for science, and chief scientific officer at NYU Langone, said in the release.
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
